A Study of LY2157299 in Participants With Hepatocellular Carcinoma

NCT01246986 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: LY2157299
DRUG: Sorafenib
DRUG: Ramucirumab

Sponsor

Eli Lilly and Company